Development of Risedronate Sodium-loaded Nanosponges by Experimental Design: Optimization and in vitro Characterization

被引:6
作者
Pandya, K. D. [1 ]
Shah, N., V [1 ]
Gohil, D. Y. [1 ]
Seth, A. K. [1 ]
Aundhia, C. J. [1 ]
Patel, S. S. [1 ]
机构
[1] Sumandeep Vidyapeeth, Dept Pharm, Piparia 391760, Vadodara, India
关键词
Risedronate sodium nanosponges; quasi-emulsion solvent diffusion; 32 full factorial design; in vitro buoyancy; in vitro drug release; ORAL BIOAVAILABILITY ENHANCEMENT; DRUG-DELIVERY; BISPHOSPHONATES; GUIDELINES; RALOXIFENE; FRACTURES; DIAGNOSIS;
D O I
10.4172/pharmaceutical-sciences.1000512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present investigation focussed on the development of a novel strategy to enhance the bioavailability of risedronate sodium, which has poor and erratic absorption. Nanosponges were statistically developed by full 32 factorial design using Design of Experiment software considering concentration of polymer and stabilizer as independent variables and particle size and entrapment efficiency as experimental responses by utilizing the modified quasi-emulsion solvent diffusion technique. Optimized formulation showed 67.27 +/- 1.05 % entrapment efficiency, 155.8 +/- 2.17 nm particle size and -35.4 mV of zeta potential. The data from in vitro release study showed burst release for initial 2 h followed by slow and sustained release up to 24 h, which followed a diffusion-controlled release mechanism by the Higuchi model. Scanning electron microscopy study showed uniformly discrete spherical particles with porous surface without any agglomeration. Stability study demonstrated no significant changes in particle size, entrapment efficiency and in vitro release, which indicated that the nanosponge formulation was stable. In conclusion, it appeared that the nanosponges were a suitable nanocarrier system that could play a significant role in improving osteoporotic condition.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 24 条
[1]  
Biernacka J, 2013, ACTA POL PHARM, V70, P877
[2]  
Brown JP, 2002, CAN MED ASSOC J, V167, pS1
[3]   Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules [J].
Dave, Vivek S. ;
Gupta, Deepak ;
Yu, Monica ;
Phuong Nguyen ;
Gupta, Sheeba Varghese .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (02) :177-189
[4]   Preparation and characterization of TiO2 nanosponge [J].
Guo, Linlin ;
Gao, Ge ;
Liu, Xiaoli ;
Liu, Fengqi .
MATERIALS CHEMISTRY AND PHYSICS, 2008, 111 (2-3) :322-325
[5]   A new approach to the development of assessment guidelines for osteoporosis [J].
Kanis, JA ;
Black, D ;
Cooper, C ;
Dargent, P ;
Dawson-Hughes, B ;
De Laet, C ;
Delmas, P ;
Eisman, J ;
Johnell, O ;
Jonsson, B ;
Melton, L ;
Oden, A ;
Papapoulos, S ;
Pols, H ;
Rizzoli, R ;
Silman, A ;
Tenenhouse, A .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (07) :527-536
[6]   PERSPECTIVE - THE DIAGNOSIS OF OSTEOPOROSIS [J].
KANIS, JA ;
MELTON, LJ ;
CHRISTIANSEN, C ;
JOHNSTON, CC ;
KHALTAEV, N .
JOURNAL OF BONE AND MINERAL RESEARCH, 1994, 9 (08) :1137-1141
[7]  
Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785
[8]  
Mitchell DY, 1999, BRIT J CLIN PHARMACO, V48, P536, DOI 10.1046/j.1365-2125.1999.00035.x
[9]   Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. [J].
Neer, RM ;
Arnaud, CD ;
Zanchetta, JR ;
Prince, R ;
Gaich, GA ;
Reginster, JY ;
Hodsman, AB ;
Eriksen, EF ;
Ish-Shalom, S ;
Genant, HK ;
Wang, OH ;
Mitlak, BH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (19) :1434-1441
[10]   Three Ply-Walled Microcapsules for Enhanced Pharmacokinetics of Poorly Absorbed Risedronate Sodium: Novel Stratagem Toward Osteoporosis [J].
Rawat, Purnima ;
Ahmad, Iqbal ;
Vohora, Divya ;
Ahmad, Farhan Jalees ;
Talegaonkar, Sushama .
JOURNAL OF PHARMACEUTICAL INNOVATION, 2015, 10 (02) :130-139